Post-Translational Control of TET Function in Lymphoma

淋巴瘤 TET 功能的翻译后控制

基本信息

项目摘要

TET DNA hydroxylases are alpha-ketoglutarate (αKG)-dependent enzymes that catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), thus promoting DNA demethylation. Mapping of 5hmC marks at single base resolution demonstrated that the main role of TET enzymes is to maintain gene enhancers hypomethylated and active. Enhancers are genomic areas to which transcription factors bind to modulate gene expression programs. Hyperactive clusters of enhancers that are densely occupied by transcriptional factors are termed super- enhancers and are typically found in cancer. Like promoters, enhancers/super-enhancers are regulated by their DNA methylation status, a process that often goes awry in cancer. Thus, given that active enhancers and super- enhancers are oncogenic in nature, and that TET enzymes maintain them hypomethylated and active, we postulate that increased TET activity may itself be oncogenic. Mitochondria function as signaling organelles by generating substrates that fuel epigenetic changes, including for example acetylation and methylation of DNA and histones, respectively. Recently, we and others described a subtler interplay between mitochondria and epigenetics, wherein the levels of the intermediate metabolites αKG and 2-hydroxyglutarate were found to modulate the activity of TET enzymes, thus controlling DNA methylation. These findings led us to hypothesize that intermediary metabolism plays as an important role in the control of DNA methylation. Specifically, we posited that the mitochondrial enzymes D-2- and L-2-hydroxyglutarate dehydrogenase (D2HGDH and L2HGDH), which catalyze the interconversion of 2-HG to αKG, are integral to the cross talk between mitochondrial metabolism, TET function and super-enhancer demethylation/activation. To expand on this initial concept, we sought to identify upstream signals that regulate D2HGDH and L2HGDH expression and, consequently, influence TET function and enhancer methylation/activity. Using reporter and ChIP assays, inducible cell lines and mouse models, we recently reported that MYC transcriptionally activates D2HGDH and L2HGDH and, in a D2HGDH/L2HGDH/αKG-dependent manner, induces TET function leading to DNA demethylation in vitro and in vivo. Remarkably, we discovered that the MYC/D2-L2HGDH/αKG axis also promotes the nuclear accumulation of TET1, TET2 and TET3, in association with enhanced O-GlcNAcylation, a post-translational modification executed by another mitochondrial enzyme, O-GlcNAc transferase (OGT). Further, we preliminarily showed that in in diffuse large B cell lymphoma (DLBCL), MYC levels associated with enhancer methylation and target gene expression. Together, these data uncovered a novel mitochondrial signaling axis which includes MYC at the proximal point, D2/L2HGDH and OGT at the center, and, distally, TET activity and subcellular location. In this proposal, we will use human B cell lymphoma models in vitro and in vivo, to test the overarching hypothesis that intermediary metabolism, in part due to MYC activity, induces TET function, maintains oncogenic enhancers/super-enhancers hypomethylated and active and promote cancer. Our specific aims are: AIM 1) Determine the mechanistic basis for the increased O-GlcNAcylation mediated by the MYC-D2/L2HGDH-αKG axis and its role in promoting TET nuclear localization and enhancer activation. AIM 2) Define the contribution of the TET activation to MYC-driven lymphomagenesis AIM 3) Characterize the MYC- driven map of 5hmC marks and super-enhancer activation in B cell lymphoma. The proposed study is significant because it will define, and mechanistically elucidate, a novel role for MYC in cancer, i.e., activation of oncogenic enhancers/super-enhancers. Downstream to MYC, the contribution of D2HGDH-L2HGDH (via αKG generation) and O-GlucNAcylation will impart a post-translational control of TET function, which challenges the current dogma that these enzymes function exclusively as tumor suppressors.
TET DNA羟化酶是α -酮戊二酸(αKG)依赖性酶,催化5mC的氧化

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma.
环磷酸腺苷信号传导、MYC 和缺氧诱导因子 1α 交叉调节 B 细胞淋巴瘤的血管生成。
  • DOI:
    10.1111/bjh.18196
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    6.5
  • 作者:
    Ethiraj,Purushoth;Sasi,Binu;Holder,KennethN;Lin,An-Ping;Qiu,Zhijun;Jaafar,Carine;Elkhalili,Alia;Desai,Parth;Saksena,Annapurna;Ritter,JacobP;Aguiar,RicardoCT
  • 通讯作者:
    Aguiar,RicardoCT
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases.
  • DOI:
    10.1038/s41375-021-01489-7
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    11.4
  • 作者:
    Lin AP;Qiu Z;Ethiraj P;Sasi B;Jaafar C;Rakheja D;Aguiar RCT
  • 通讯作者:
    Aguiar RCT
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ricardo C Aguiar其他文献

Ricardo C Aguiar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ricardo C Aguiar', 18)}}的其他基金

Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10117575
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10322194
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10541234
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Oxidative stress and RNA methylation
氧化应激和 RNA 甲基化
  • 批准号:
    10330584
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Oxidative stress and RNA methylation
氧化应激和 RNA 甲基化
  • 批准号:
    10569629
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Post-Translational Control of TET Function in Lymphoma
淋巴瘤 TET 功能的翻译后控制
  • 批准号:
    10251482
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
IRF8 and lymphomagenesis
IRF8 和淋巴瘤发生
  • 批准号:
    9898227
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
  • 批准号:
    8974297
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
IRF8 and lymphomagenesis
IRF8 和淋巴瘤发生
  • 批准号:
    9235548
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
  • 批准号:
    8436704
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了